企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
Pharos iBio Co., Ltd. is an AI (artificial intelligence)-based innovative new drug development venture company (classified under 'medical and pharmaceutical research and development' in the Korea Standard Industrial Classification) founded in Anyang, Gyeonggi-do in 2016, and develops innovative new drugs focused on rare and intractable diseases using its self-built AI-based new drug development platform 'Chemiverse', based on its multidisciplinary research capabilities in engineering, chemistry, and biology. Based on analysis of the three-dimensional structure and drug-binding sites of disease-related (particularly oncology) target proteins, the company calculates the interaction energy between drugs and targets, and holds the Chemiverse platform technology, which consists of nine modules with functions including drug toxicity prediction and new target indication prediction.
代表理事
Yoon Jeonghyeok
成立日期
2016年4月19日
法人类型
韩国创业板
行业分类
Research and experimental development on medical sciences and pharmacy
法人注册号
13111-0444346
营业执照号
409-87-00402
电话号码
070-7662-8585
传真号码
02-6348-6185
公司地址
288 Digital-ro, Guro-gu, Seoul
产品与服务
评论